Recorded on December 9, 2022
Join CLL Society and PeerView Institute to hear discussions about how integrating targeted therapeutics, including second-generation BTK inhibitors and emerging cellular therapies, can improve care across the clinical spectrum of CLL during this ASH 2022 Symposium, taking place both live and virtually.
This symposium includes a panel of leading chronic lymphocytic leukemia experts who blend case-based discussions with short lectures to illustrate how integrating targeted therapeutics can improve care across the CLL spectrum. Hear about important clinical topics such as the personalized, evidence-based selection of upfront treatment strategies; therapeutic sequencing in progressive disease settings; safety management and distinctions among agent classes; the use of MRD assessment as a treatment tool; and next-generation and novel combinatorial strategies. Featuring experts such as Drs. John G. Gribben, Barbara Eichhorst, Nitin Jain, and Anthony R. Mato, as well as 22-year CLL survivor Terry Evans.
